Treatment Options for COVID-19: Evidence Review for Promising Candidates .
Promising antiviral treatments for COVID-19—molnupiravir, baricitinib, tofacitinib, and casirivimab/imdevimab—have shown efficacy and safety in clinical trials, as attention is now shifting toward antiviral drugs that can be taken early in infection to prevent severe COVID-19. Early trial data are encouraging: molnupiravir shows meaningful antiviral activity and appears well tolerated. JAK inhibitors like baricitinib and tofacitinib have reduced mortality or clinical worsening in hospitalized patients. Casirivimab/imdevimab offers clear benefit for seronegative patients. While each therapy targets a different phase of illness, together they highlight a growing toolbox that complements vaccination—and underscores the value of continued research as the virus evolves.
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!